





1

 **The Investigational New Drug (IND) Process: *Basic II***

☐ **Session Objectives**

- **Attendees will learn**
  - **The format and content of assembling an IND**



2

## >> The Investigational New Drug (IND) Process: *Basic II*

### ❑ IND Content and Format Covered in 21 CFR 312.23

#### ❑ Format of an IND

- As of May 2018, commercial INDs must be submitted using the FDA's electronic gateway
- In order to use the gateway, the IND must be formatted using the structure outlined in the Common Technical Document (CTD) guidelines
  - However, the CTD was designed for NDAs/BLAs/Marketing Applications
- Many Sponsors try to follow the CTD for both format and content
  - However, many (most) of the sections of the CTD do not apply to INDs
    - ❖ For example: Clinical Overview (Module 2.5)
      - ✓ "The Clinical Overview is intended to provide a critical analysis of the clinical data in the Common Technical Document"
      - ✓ How can there be a "critical analysis of clinical data" in an IND for a "first-in-human" study?



3

## >> The Investigational New Drug (IND) Process: *Basic II*

### ❑ Format of an IND (cont'd)

- As summarized on subsequent slides, the general contents of an IND are based on 21 CFR 312.23 (IND content and format)
- The FDA has adopted the CTD format (not content) to allow for the electronic submission of the IND
- That means the various IND documents are "mapped" to a location in the CTD structure/format.
- For example, the Introductory Statement maps to CTD module 2.2 (Introduction to Summaries), the Investigator's Brochure maps to Module 1.14.4.1, etc.



4

## >> IND Content

### ❑ IND Content

IND Content	IND Comments	"Maps to" CTD Location
Cover Letter	All IND-related submissions require a cover letter. The cover letter will serve as a "road map" for the submission and introduce the FDA to the application.	1.2 / Cover letters
Form FDA 1571	Standard form that accompanies all IND submissions.	1.1.1 / Application form: FDA form 1571
Form FDA 3674	Certificate of compliance with Clinicaltrials.gov	1.1.2 / Forms

5

## >> IND Content

### ❑ IND Content (cont'd)

IND Content	IND Comments	"Maps to" CTD Location
Introductory Statement	The <u>brief</u> introductory statement provides: name of the drug and all active ingredients, the drug's pharmacological class, the structural formula of the drug, the formulation of the dosage form, the route of administration, the broad objectives and planned duration of the proposed clinical investigation, and brief summary of previous human experience (if applicable). This is usually ~2 pages.	2.2 / Introduction to Summary

6

## >> IND Content

### ❑ IND Content (cont'd)

IND Content	IND Comments	"Maps to" CTD Location
General Investigational Plan	A <u>brief</u> description of the overall plan for investigating the drug product for the upcoming year. This is usually 1-2 pages. It is non-binding. The purpose is to give the FDA an idea of sponsor's development plans for the upcoming year. It is <u>not</u> meant to summarize the protocol(s) that are submitted with the IND.	1.13.9 / General Investigational Plan



7

## >> IND Content

### ❑ IND Content (cont'd)

IND Content	IND Comments	"Maps to" CTD Location
Investigator's Brochure	The IB should summarize the development activities (brief summary of the indication to be studied; chemical name, structure, dosage form; preclinical pharmacology, PK, and toxicology; previous human experience (if applicable); and a section entitled: Summary of Data and Guidance for the Investigator. This section should include an integrated toxicology summary with an overall conclusion regarding toxicity implications to humans.	1.14.4.1 / Investigator's Brochure

8

## >> IND Content

### ❑ IND Content (cont'd)

IND Content	IND Comments	"Maps to" CTD Location
Protocol	The final, full protocol (or protocols) to be included in the IND and investigator documentation (CV and 1572 Form)	5.3 / Clinical Study Reports and Related Information



9

## >> IND Content

### ❑ IND Content (cont'd)

IND Content	IND Comments	"Maps to" CTD Location
Pharmacology / PK Summaries	<p>It is recommended that the pharmacology and PK summaries that are included in this section of the IND be identical to the summary of pharm/PK summaries that are included in the IB</p> <p>Brief summaries will suffice for nonclinical studies and should include, at a minimum: introduction, materials, methods, data, and brief conclusion</p>	<p>2.6.2 / Pharmacology Written Summary</p> <p>2.6.4 / PK Written Summary</p> <p><i>Note: IND <u>does not</u> require "tabulated" summaries.</i></p>

10

## » IND Content

### □ IND Content (cont'd)

IND Content	IND Comments	"Maps to" CTD Location
Toxicology Summary	<p>As noted above, it is recommended that the summary of the toxicology studies be identical to the summary of toxicology studies that are included in the IB</p> <p>Please note: All toxicology studies conducted with the API should be included. That includes pilot studies, non-GLP studies, and GLP studies. An integrated toxicology summary with an overall conclusion regarding toxicity implications to humans is expected.</p>	<p>2.6.6 / Toxicology Written Summary</p> <p><i>Again, a Toxicology Tabulated Summary is not required.</i></p>

11

## » IND Content

### □ IND Content (cont'd)

IND Content	IND Comments	"Maps to" CTD Location
Drug Substance / Drug Product	<p>This section will describe the composition, manufacture, and control of the drug substance (active pharmaceutical ingredient, API) and the drug product in sufficient detail to assure the proper identification, quality, purity, and strength of the investigational drug. Available stability data (API and drug product) are to be included. Information on lot(s) of API used in toxicology studies needs to be included. Similarly, information on lot(s) used in clinical study needs to be included.</p>	<p>Module 3</p> <p><i>Note: A summary of CMC information is not required. Nor is a "Quality Overall Summary".</i></p>

12

## » IND Content

### ❑ IND Content (cont'd)

IND Content	IND Comments	"Maps to" CTD Location
Placebo	This section should also describe the manufacture of the placebo that will be used in clinical trial, if applicable.	Part of Module 3
Investigational Label	The only <u>required</u> wording is: "Caution: New Drug--Limited by federal (or US) law to investigational use"; however, most labels include the name of the investigational drug, manufacturer, retest/expiry date, sponsor, contact phone number, and directions for use	1.14.4.2 / Investigational Drug Labeling

13

## » IND Content

### ❑ IND Content (cont'd)

IND Content	IND Comments	"Maps to" CTD Location
Environmental Assessment	<p>A claim for categorical exclusion under 21 CFR 25.30 regarding environmental assessment is required. This is a standard statement.</p> <p>"In accordance with 21 CFR 25.32, the Sponsor requests a categorical exclusion from providing an environmental assessment."</p>	1.12.14 / Environmental analysis

14

## » IND Content

### □ IND Content (cont'd)

#### ▪ Detailed structure of Module 3/Drug Substance:

##### 3.2.S Drug Substance

##### 3.2.S.1 General Information

##### 3.2.S.2 Manufacture

##### 3.2.S.2.1 Manufacturer(s)

##### 3.2.S.2.2 Description of Manufacturing Process and Process Controls

##### 3.2.S.2.3 Control of Materials

##### 3.2.S.2.4 Controls of Critical Steps and Intermediates

##### 3.2.S.2.5 Process Validation: NA for INDs

##### 3.2.S.2.6 Manufacturing Process Development

##### 3.2.S.3 Characterization

##### 3.2.S.4 Control of Drug Substance

##### 3.2.S.5 Reference Standards or Materials

##### 3.2.S.6 Container Closure Systems

##### 3.2.S.7 Stability



15

## » IND Content

### □ IND Content (cont'd)

IND Content	IND Comments	"Maps to" CTD Location
Nonclinical Full Reports: Pharmacology PK Safety Pharm Toxicology	<p>Full reports of the nonclinical studies required.</p> <p>Note: FDA will review nonclinical reports, especially safety pharmacology and toxicology, and compare to the IB to make sure all studies are included in both the IB and Module 4.</p> <p>Data from toxicology and safety pharmacology studies must comply with the Standards for Exchange of Nonclinical Data (SEND) format.</p>	Module 4

16



## IND Content

- ❑ **IND Content (cont'd)**
  - **Detailed content of Module 4**
    - 4.2 Study reports**
      - 4.2.1 Pharmacology**
        - 4.2.1.1 Primary pharmacodynamics**
        - 4.2.1.2 Secondary pharmacodynamics**
        - 4.2.1.3 Safety pharmacology**
      - 4.2.2 Pharmacokinetics**
        - 4.2.2.1 Analytical methods**
        - 4.2.2.2 Absorption**
        - 4.2.2.3 Distribution**
        - 4.2.2.4 Metabolism**
        - 4.2.2.5 Excretion**

17

## IND Content

- ❑ **IND Content (cont'd)**
  - **Detailed content of Module 4 (cont'd)**
    - 4.2.3 Toxicology**
      - 4.2.3.1 Single dose toxicity [Species and route of administration]**
      - 4.2.3.2 Repeat dose toxicity [Species, route, duration]**
      - 4.2.3.3 Genotoxicity**
      - 4.2.3.4 Carcinogenicity**
      - 4.2.3.5 Reproductive and developmental toxicity**
      - 4.2.3.6 Local tolerance**
      - 4.2.3.7 Other toxicity studies**

18

## IND Content

### ❑ IND Content (cont'd)

IND Content	IND Comments	“Maps to” CTD Location
Previous Human Experience	<p>A summary of previous human experience is to be included. It is acceptable to replicate the clinical section of the Investigators’ Brochure for this section. If the IND protocol is “first-in-human”, this section is NA.</p> <p><i>Full clinical reports are not required.</i></p> <p>If full clinical reports are to be submitted, they should be placed in the appropriate section of Module 5.</p>	<p>2.7 / Clinical Summary</p> <p>Module 5</p>

19

## The Investigational New Drug (IND) Process: *Basic II*

 **Next Session: Meetings with the FDA: *Advanced***

- **Attendees will learn about**

- **How to prepare the Meeting Package**
- **Operational activities associated with the meeting**
  - ✓ **Preliminary responses, meeting preparation, attending the meeting, etc.**
- **Recommendations for a successful meeting**

 **Questions?**

20



21